Cerebrovasc Dis 2008;25:192
DOI: 10.1159/000113740

**Correction to the ProFESS Trial Paper by
Diener et al. (Cerebrovasc Dis 2007;23:368–380)**

R. Sacco, H.C. Diener, S. Yusuf, on behalf of the Steering Committee

Dear Journal Editor

The Trial Management Committee of the study, without any knowledge of results, has developed a detailed statistical analysis plan. In this process, one important modification has been made that relates to testing whether there is an interaction between the effects of telmisartan and placebo and between aggrenox and clopidogrel. We believe that there is no a priori expectation of an interaction in the treatment effects. Therefore to minimize the risks of claiming a spurious interaction, we have decided to test for an interaction at an α level of 0.01. If however an interaction at the 0.05 level is detected, this will be only considered to be significant if this is supported by consistent interactions that are also statistically significant at 0.05 on related secondary outcomes (two composite endpoints of stroke, myocardial infarction, vascular death and stroke, vascular death, new or worsening congestive heart failure, respectively).

Respectfully submitted,

Prof. R. Sacco

Prof. H.C. Diener

Prof. S. Yusuf